I think it is "popular in these parts" in part bc it does NOT have a lot of moving parts and is fairly easy to understand- all of 2 programs, w one accounting for 90% of the current valuation I do think competition from biosimilar epo, competition from future HIFPH inhibitors, risk inherent w a novel MOA and the fairly high market cap for a development stage bio are all reasonable concerns of course
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.